Repository logo
 
Publication

Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: Contemporaneous Portuguese cross-sectional data

2019Journal article Open access
Simple item page
dc.contributor.authorCaldeira, D
dc.contributor.authorPereira, H
dc.contributor.authorMarques, A
dc.contributor.authorAlegria, S
dc.contributor.authorCalisto, J
dc.contributor.authorSilva, P
dc.contributor.authorRibeiro, V
dc.contributor.authorSilva, JC
dc.contributor.authorSeixo, F
dc.contributor.authorAbreu, PF, et al.
dc.date.accessioned2020-07-08T14:10:28Z
dc.date.available2020-07-08T14:10:28Z
dc.date.issued2019
dc.description.abstractINTRODUCTION: The standard of care for acute ST-elevation myocardial infarction (STEMI) includes the activation of a STEMI care network, the administration of adjuvant medical therapy, and reperfusion through primary percutaneous coronary intervention (PCI). While primary PCI is nowadays the first option for the treatment of patients with STEMI, antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of pharmacological treatment to optimize their clinical outcomes. OBJECTIVE: The aim of this study was to describe contemporaneous real-world patterns of use of antithrombotic treatments in Portugal for STEMI patients undergoing primary PCI. METHODS: An observational, retrospective cross-sectional study was performed for the year 2016, based on data from two national registries: the Portuguese Registry on Acute Coronary Syndromes (ProACS) and the Portuguese Registry on Interventional Cardiology (PRIC). Data on oral antiplatelet and procedural intravenous antithrombotic drugs were retrieved. RESULTS: In 2016, the ProACS enrolled 534 STEMI patients treated with primary PCI, while the PRIC registry reported data on 2625 STEMI patients. Of these, 99.6% were treated with aspirin and 75.6% with dual antiplatelet therapy (mostly clopidogrel). GP IIb/IIIa inhibitors (mostly abciximab) were used in 11.6% of cases. Heparins were used in 80% of cases (78% unfractionated heparin [UFH] and 2% low molecular weight heparin). None of the patients included in the registry were treated with cangrelor, prasugrel or bivalirudin. Missing data are one of the main limitations of the registries. CONCLUSIONS: In 2016, according to data from these national registries, almost all patients with STEMI were treated with aspirin and 76% with dual antiplatelet agents, mostly clopidogrel. GP IIb/IIIa inhibitors were used in few patients, and UFH was the most prevalent parenteral anticoagulant drug.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRev Port Cardiol. 2019 Nov;38(11):809-814pt_PT
dc.identifier.doi10.1016/j.repc.2019.02.015pt_PT
dc.identifier.issn2174-2030
dc.identifier.urihttp://hdl.handle.net/10400.10/2468
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionfile:///U:/Desktop/1-s2.0-S087025512030007X-main.pdfpt_PT
dc.subjectMyocardial infarctionpt_PT
dc.subjectPercutaneous coronary interventionpt_PT
dc.subjectThrombolytic therapypt_PT
dc.subjectFibrinolytic agentspt_PT
dc.subjectPortugalpt_PT
dc.titleAdjuvant antithrombotic therapy in ST-elevation myocardial infarction: Contemporaneous Portuguese cross-sectional datapt_PT
dc.title.alternativeTerapêutica antitrombótica adjuvante no enfarte do miocárdio com elevação do segment ST: dados portugueses transversais contemporâneospt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceLisbonpt_PT
oaire.citation.titleRevista portuguesa de cardiologiapt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S087025512030007X-main.pdf
Size:
589.15 KB
Format:
Adobe Portable Document Format
Download

Collections

CAR - Artigos publicados em revistas indexadas